2-Apr-2026
No headlines found.
Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
PRNewswire (Tue, 24-Mar 7:00 AM ET)
Faster Cardiac Answers with High-Sensitivity Troponin
PRNewswire (Thu, 19-Feb 9:17 AM ET)
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
PRNewswire (Wed, 18-Feb 4:05 PM ET)
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
PRNewswire (Wed, 11-Feb 4:05 PM ET)
QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie Awards
PRNewswire (Tue, 3-Feb 7:12 AM ET)
Strengthening the blood supply: Awareness, challenges and donor impact
PRNewswire (Thu, 22-Jan 7:12 AM ET)
QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
PRNewswire (Wed, 21-Jan 7:00 AM ET)
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Quidelortho trades on the NASDAQ stock market under the symbol QDEL.
As of April 2, 2026, QDEL stock price climbed to $17.25 with 1,087,632 million shares trading.
QDEL has a beta of 2.07, meaning it tends to be more sensitive to market movements. QDEL has a correlation of 0.22 to the broad based SPY ETF.
QDEL has a market cap of $1.17 billion. This is considered a Small Cap stock.
Last quarter Quidelortho reported $724 million in Revenue and $.46 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.03.
In the last 3 years, QDEL traded as high as $98.67 and as low as $14.45.
The top ETF exchange traded funds that QDEL belongs to (by Net Assets): IJR, VTI, AVUV, VB, IWM.
QDEL has underperformed the market in the last year with a return of -49.4%, while the SPY ETF gained +18.2%. In the last 3 month period, QDEL fell short of the market, returning -39.6%, while SPY returned -3.6%. However, in the most recent 2 weeks QDEL has outperformed the stock market by returning +1.3%, while SPY returned -0.6%.
QDEL support price is $15.73 and resistance is $17.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QDEL shares will trade within this expected range on the day.